Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Separate or United: The Safety Net in the Era of Health Care Integration.

Gabow PA, Smith M.

J Health Care Poor Underserved. 2017;28(3):853-859. doi: 10.1353/hpu.2017.0082.

PMID:
28804063
2.

Closing the Health Care Gap in Communities: A Safety Net System Approach.

Gabow PA.

Acad Med. 2016 Oct;91(10):1337-1340.

PMID:
27556674
3.

A broad and structured approach to improving patient safety and quality: lessons from Denver Health.

Gabow PA, Mehler PS.

Health Aff (Millwood). 2011 Apr;30(4):612-8. doi: 10.1377/hlthaff.2011.0042.

PMID:
21471480
4.

Denver Health. Transforming care across the continuum.

Gabow PA.

Hosp Health Netw. 2010 May;84(5):57. No abstract available.

PMID:
20575351
5.

Inspired leadership: Dr. Patricia Gabow talks about pursuing transformation and why mentoring matters.

Gabow PA.

Mod Healthc. 2008 Nov;Suppl:27-9. No abstract available.

PMID:
19133354
6.

Changes in insurance status and access to care in an integrated safety net healthcare system.

Eisert SL, Durfee MJ, Welsh A, Moore SL, Mehler PS, Gabow PA.

J Community Health. 2009 Apr;34(2):122-8. doi: 10.1007/s10900-008-9136-2.

PMID:
18941874
7.

Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history.

Reed B, McFann K, Kimberling WJ, Pei Y, Gabow PA, Christopher K, Petersen E, Kelleher C, Fain PR, Johnson A, Schrier RW.

Am J Kidney Dis. 2008 Dec;52(6):1042-50. doi: 10.1053/j.ajkd.2008.05.015. Epub 2008 Jul 21.

8.

Can America's urban safety net systems be a solution to unequal treatment?

Eisert SL, Mehler PS, Gabow PA.

J Urban Health. 2008 Sep;85(5):766-78. doi: 10.1007/s11524-008-9296-5. Epub 2008 Jun 14.

9.

Observations of residents' work activities for 24 consecutive hours: implications for workflow redesign.

Gabow PA, Karkhanis A, Knight A, Dixon P, Eisert S, Albert RK.

Acad Med. 2006 Aug;81(8):766-75.

PMID:
16868436
10.

Prevalence of psychiatric disorders and costs of care among adult enrollees in a Medicaid HMO.

Thomas MR, Waxmonsky JA, Gabow PA, Flanders-McGinnis G, Socherman R, Rost K.

Psychiatr Serv. 2005 Nov;56(11):1394-401.

PMID:
16282258
11.

Repeat imaging for intracranial aneurysms in patients with autosomal dominant polycystic kidney disease with initially negative studies: a prospective ten-year follow-up.

Schrier RW, Belz MM, Johnson AM, Kaehny WD, Hughes RL, Rubinstein D, Gabow PA.

J Am Soc Nephrol. 2004 Apr;15(4):1023-8.

12.

Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease.

Belz MM, Fick-Brosnahan GM, Hughes RL, Rubinstein D, Chapman AB, Johnson AM, McFann KK, Kaehny WD, Gabow PA.

Kidney Int. 2003 May;63(5):1824-30.

13.

Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease.

Belz MM, Hughes RL, Kaehny WD, Johnson AM, Fick-Brosnahan GM, Earnest MP, Gabow PA.

Am J Kidney Dis. 2001 Oct;38(4):770-6.

PMID:
11576880
14.

Making a public hospital work.

Gabow PA.

Health Aff (Millwood). 2001 Jul-Aug;20(4):182-7. No abstract available.

PMID:
11463075
15.

Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease.

Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, Schrier RW.

Am J Nephrol. 2001 Mar-Apr;21(2):98-103.

PMID:
11359016
16.

Progression of autosomal-dominant polycystic kidney disease in children.

Fick-Brosnahan GM, Tran ZV, Johnson AM, Strain JD, Gabow PA.

Kidney Int. 2001 May;59(5):1654-62.

17.

Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease.

Chatha RK, Johnson AM, Rothberg PG, Townsend RR, Neumann HP, Gabow PA.

Am J Kidney Dis. 2001 Apr;37(4):852-8.

PMID:
11273887
18.

CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease.

Persu A, Devuyst O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C.

J Am Soc Nephrol. 2000 Dec;11(12):2285-96.

19.

Progress in blood pressure control in autosomal dominant polycystic kidney disease.

Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Duley IT, Gabow PA, Schrier RW.

Am J Kidney Dis. 2000 Aug;36(2):266-71.

PMID:
10922304
20.

Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease.

Sharp CK, Zeligman BE, Johnson AM, Duley I, Gabow PA.

Am J Kidney Dis. 1999 Nov;34(5):863-8.

PMID:
10561142
21.

Renal asymmetry in children with autosomal dominant polycystic kidney disease.

Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA.

Am J Kidney Dis. 1999 Oct;34(4):639-45.

PMID:
10516343
22.

Frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease.

Stamm ER, Townsend RR, Johnson AM, Garg K, Manco-Johnson M, Gabow PA.

Am J Kidney Dis. 1999 Jul;34(1):120-4.

PMID:
10401025
23.

From the bedside to the boardroom.

Gabow PA.

Semin Nephrol. 1999 Mar;19(2):109-14.

PMID:
10192242
24.

Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.

O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ.

Am J Kidney Dis. 1998 Dec;32(6):976-83.

PMID:
9856513
25.

Hypertension in autosomal dominant polycystic kidney disease.

Chapman AB, Gabow PA.

Kidney Int Suppl. 1997 Oct;61:S71-3. Review. No abstract available.

PMID:
9328971
27.

Denver Health: initiatives for survival.

Gabow PA.

Health Aff (Millwood). 1997 Jul-Aug;16(4):24-6. No abstract available.

PMID:
9248146
28.

A peer approach to high risk youth.

Hritz SA, Gabow PA.

J Adolesc Health. 1997 Apr;20(4):259-60.

PMID:
9098728
29.

Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children.

Gabow PA, Kimberling WJ, Strain JD, Manco-Johnson ML, Johnson AM.

J Am Soc Nephrol. 1997 Jan;8(1):105-10.

30.

PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein.

Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJ, Somlo S.

Science. 1996 May 31;272(5266):1339-42.

PMID:
8650545
31.

Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease.

Golin CO, Johnson AM, Fick G, Gabow PA.

Am J Kidney Dis. 1996 Feb;27(2):220-3.

PMID:
8659497
32.

Genetic studies in a black family with autosomal dominant polycystic kidney disease and sickle-cell trait.

Kimberling WJ, Yium JJ, Johnson AM, Gabow PA, Martinez-Maldonado M.

Nephron. 1996;72(4):595-8.

PMID:
8730427
33.

Improving identification of and intervention for alcoholism.

Mehler PS, McClellan MD, Lezotte D, Casper E, Gabow PA.

West J Med. 1995 Oct;163(4):335-40.

34.

Causes of death in autosomal dominant polycystic kidney disease.

Fick GM, Johnson AM, Hammond WS, Gabow PA.

J Am Soc Nephrol. 1995 Jun;5(12):2048-56. Review.

35.

Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease.

Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA.

J Am Soc Nephrol. 1995 Jun;5(12):2032-6.

36.

Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease.

Chapman AB, Johnson AM, Gabow PA, Schrier RW.

J Am Soc Nephrol. 1994 Dec;5(6):1349-54.

37.
38.

Hereditary and acquired cystic disease of the kidney.

Fick GM, Gabow PA.

Kidney Int. 1994 Oct;46(4):951-64. Review. No abstract available.

39.

Futile care: prevention and process: educating patients about advance directives is crucial.

Parsons PE, Kobayashi JS, Gabow PA.

J Crit Illn. 1994 Sep;9(9):856-69.

PMID:
10147463
40.

Concepts and controversies in salicylate toxicity.

Yip L, Dart RC, Gabow PA.

Emerg Med Clin North Am. 1994 May;12(2):351-64. Review.

PMID:
8187688
41.

Is there evidence for anticipation in autosomal-dominant polycystic kidney disease?

Fick GM, Johnson AM, Gabow PA.

Kidney Int. 1994 Apr;45(4):1153-62.

42.

The spectrum of autosomal dominant polycystic kidney disease in children.

Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA.

J Am Soc Nephrol. 1994 Mar;4(9):1654-60.

43.

Natural history of autosomal dominant polycystic kidney disease.

Fick GM, Gabow PA.

Annu Rev Med. 1994;45:23-9. Review.

PMID:
8198379
44.

Autosomal dominant polycystic kidney disease: localization of the second gene to chromosome 4q13-q23.

Kimberling WJ, Kumar S, Gabow PA, Kenyon JB, Connolly CJ, Somlo S.

Genomics. 1993 Dec;18(3):467-72.

PMID:
8307555
45.

Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: how to diagnose and who to screen.

Chapman AB, Johnson AM, Gabow PA.

Am J Kidney Dis. 1993 Oct;22(4):526-31. Review. No abstract available.

PMID:
8213791
46.

Autosomal dominant polycystic kidney disease.

Gabow PA.

Am J Kidney Dis. 1993 Oct;22(4):511-2. No abstract available.

PMID:
8213788
47.

Autosomal dominant polycystic kidney disease.

Gabow PA.

N Engl J Med. 1993 Jul 29;329(5):332-42. Review. No abstract available.

PMID:
8321262
48.

Characteristics of very early onset autosomal dominant polycystic kidney disease.

Fick GM, Johnson AM, Strain JD, Kimberling WJ, Kumar S, Manco-Johnson ML, Duley IT, Gabow PA.

J Am Soc Nephrol. 1993 Jun;3(12):1863-70.

49.

Intracranial aneurysms in autosomal dominant polycystic kidney disease.

Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD.

N Engl J Med. 1992 Sep 24;327(13):916-20.

50.

Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease.

Gabow PA, Duley I, Johnson AM.

Am J Kidney Dis. 1992 Aug;20(2):140-3.

PMID:
1496966

Supplemental Content

Loading ...
Support Center